C4 Therapeutics Added to NASDAQ Biotechnology Index
C4 Therapeutics, Inc. (Nasdaq: CCCC), a clinical-stage biopharmaceutical company, has been included in the NASDAQ Biotechnology Index, effective December 20, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
C4 Therapeutics, Inc. (Nasdaq: CCCC), a clinical-stage biopharmaceutical company, has been included in the NASDAQ Biotechnology Index, effective December 20, 2021. This index tracks notable biotechnology and pharmaceutical companies listed on NASDAQ, requiring eligibility criteria such as minimum market capitalization and average daily trading volume of 100,000 shares. C4 Therapeutics focuses on developing drugs that selectively degrade disease-causing proteins, offering advantages like reduced drug resistance and side effects. The company aims to target cancer and other diseases.
Positive
- Inclusion in the NASDAQ Biotechnology Index enhances visibility and credibility among investors.
- Focus on targeted protein degradation may lead to innovative therapies with higher efficacy and reduced side effects.
Negative
- None.
Details
News Market Reaction – CCCC
The recorded move for CCCC in the trading session of this news was +3.08%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced its inclusion on the NASDAQ Biotechnology Index (Nasdaq: NBI), effective on December 20, 2021.
The NASDAQ Biotechnology Index tracks the performance of a set of biotechnology and pharmaceutical companies, classified by the Industry Classification Benchmark (ICB), currently listed on the NASDAQ stock exchange. Securities in this index must meet eligibility criteria including being listed on the NASDAQ Global Select Market or the NASDAQ Global Market. Securities must also meet market capitalization standards and maintain a minimum average daily trading volume (ADTV) of 100,000 shares.
More information about the NASDAQ Biotechnology index is available at nasdaqomx.com.
About C4 Therapeutics
C4 Therapeutics (C4T) is a clinical-stage biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity. To learn more about C4 Therapeutics, visit www.c4therapeutics.com.
Investor Contact:
Kendra Adams
SVP, Communications & Investor Relations
Kendra.Adams@c4therapeutics.com
Media Contact:
Loraine Spreen
Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.